About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Nashville | 20,298 Studies Near You | Clareo Health

Clinical Trials LocationsNashville

Clinical Trials in Nashville

Discover 20,298 clinical trials near Nashville, Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 6261-6280 of 20,298 trials

COMPLETEDNA< 1 mile

Visualizing Vascular Mechanisms of Salt Sensitivity

NCT03696433

This study aims to assess the salt sensitive blood pressure response to dietary salt load compared with radiological markers of salt handling.

ObesityCardiovascular Risk FactorSalt; Excess

Vanderbilt University Medical Center19 participantsStarted Feb 2019

Nashville, Tennessee, United States

COMPLETEDPhase 417 miles

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Parkinson Disease Psychosis

ACADIA Pharmaceuticals Inc.29 participantsStarted Feb 2020

Scottsdale, Arizona, United States • Fullerton, California, United States • Miami, Florida, United States +15 more locations

Find Trials by Condition in Nashville

Breast Cancerin Nashville Lung Cancerin Nashville Prostate Cancerin Nashville Colorectal Cancerin Nashville Melanomain Nashville Leukemiain Nashville Lymphomain Nashville Pancreatic Cancerin Nashville Ovarian Cancerin Nashville Brain Cancerin Nashville

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2128 miles

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057

This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating patients with kidney cancer compared to sunitinib malate.

Locally Advanced Papillary Renal Cell CarcinomaMetastatic Papillary Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v7+4 more

National Cancer Institute (NCI)152 participantsStarted Jul 2016

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +592 more locations

COMPLETEDPhase 2132 miles

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

NCT04451772

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination (elsubrutinib/upadacitinib) works within the body, in participants who completed study M19-130. This study will assess the change in disease symptoms. ABBV-599 is an investigational drug being developed for the treatment of Systemic Lupus Erythematosus (SLE). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of SLE will be enrolled. Around 260 participants will be enrolled in the study in approximately 100 sites worldwide. Participants will receive the following for up to 56 weeks: Participants will receive oral elsubrutinib capsules and/or oral upadacitinib tablets once daily for up to 56 weeks. Participants who were receiving elsubrutinib and/or upadacitnib in M19-130 will continue to receive the same treatment in this study. Participants who were receiving placebo in M19-130 will be re-randomized to one of the 2 combination treatment arms in this study. Arm 1: Elsubrutinib Dose A and Upadacitinib Dose A Arm 2: Elsubrutinib Dose A and Upadacitinib Dose B There may be higher burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Systemic Lupus Erythematosus (SLE)

AbbVie185 participantsStarted Jul 2020

Phoenix, Arizona, United States • Beverly Hills, California, United States • Los Alamitos, California, United States +84 more locations

Active Not RecruitingPhase 2155 miles

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

NCT03709680

A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).

Ewing SarcomaSolid TumorsRhabdoid Tumor+4 more

Pfizer128 participantsStarted May 2019

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Long Beach, California, United States +98 more locations

Active Not RecruitingNA183 miles

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

NCT05174767

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

Acute Aortic Dissection

Artivion Inc.115 participantsStarted May 2022

Birmingham, Alabama, United States • Los Angeles, California, United States • Palo Alto, California, United States +22 more locations

COMPLETEDPhase 4183 miles

Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

NCT03637660

This is a phase 4, randomized, open-label, multicenter trial to evaluate the efficacy of a single injected dose of Benzathine Penicillin G (BPG) 2.4 MU (Arm 1) compared to three successive weekly injected doses of BPG 2.4 MU (Arm 2) for treatment of early syphilis in human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects. The study will enroll 560 adults (to achieve 420 evaluable subjects) aged 18 years or older with untreated early syphilis (primary, secondary, or early latent). It will be conducted at 9 sites in the US and last for 48 months with patient participation duration of 12 months. The primary objective is to compare the serological response to therapy in subjects with early (primary, secondary, or early latent) syphilis treated with Benzathine Penicillin G (BPG) 2.4 million units (MU) once or weekly for three successive weeks.

National Institute of Allergy and Infectious Diseases (NIAID)249 participantsStarted Oct 2018

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Indianapolis, Indiana, United States +7 more locations

COMPLETEDNA186 miles

Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

NCT03959423

This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.

Type 1 Diabetes Mellitus

Medtronic MiniMed, Inc.288 participantsStarted Jul 2019

Little Rock, Arkansas, United States • La Jolla, California, United States • Torrance, California, United States +14 more locations

Not Yet Recruiting196 miles

Nemaline Myopathy Clinical Research Network (NM-CTRN)

NCT06774703

The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).

Nemaline Myopathy

Stanford University50 participantsStarted Jan 2025

Palo Alto, California, United States • Bethesda, Maryland, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDNA220 miles

Electronic Patient Reporting of Symptoms During Cancer Treatment

NCT03249090

The current study is designed to test nationally whether patients' outcomes and utilization of services can be improved through symptom monitoring via patient-reported outcomes between visits.

Metastatic Cancer

Alliance Foundation Trials, LLC.1,197 participantsStarted Oct 2017

Grand Junction, Colorado, United States • Lawrenceville, Georgia, United States • Harvey, Illinois, United States +42 more locations

COMPLETEDPhase 4237 miles

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773

A prospective, large, pragmatic, randomized trial to study the impact of METFORMIN and healthy lifestyle intervention (LIFE) vs. LIFE alone on patient-centered outcomes of body weight, SGA-adherence and satisfaction, psychiatric symptom burden (e.g. mood/anxiety), and Quality of Life.

Bipolar Disorder

Melissa Delbello1,565 participantsStarted Dec 2015

Covington, Kentucky, United States • Neptune City, New Jersey, United States • Amityville, New York, United States +26 more locations

COMPLETEDPhase 1/2239 miles

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at \>35 weeks gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel prior to administering the next-highest dose.

Respiratory Tract InfectionRespiratory Syncytial Virus

Merck Sharp & Dohme LLC183 participantsStarted Sep 2018

Aurora, Colorado, United States • Homestead, Florida, United States • Miami, Florida, United States +31 more locations

COMPLETEDPhase 2253 miles

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

NCT04218851

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).

Invasive Aspergillosis

Merck Sharp & Dohme LLC31 participantsStarted Jul 2020

Orange, California, United States • San Diego, California, United States • Chicago, Illinois, United States +26 more locations

COMPLETEDPhase 1/2333 miles

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

NCT01902173

This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.

Hematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced Melanoma+6 more

National Cancer Institute (NCI)27 participantsStarted Oct 2013

Los Angeles, California, United States • Los Angeles, California, United States • San Francisco, California, United States +13 more locations

TERMINATEDPhase 2365 miles

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

NCT04440982

This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.

Breast CancerNeoadjuvant Therapy

Lumicell, Inc.98 participantsStarted Sep 2020

Palo Alto, California, United States • Clearwater, Florida, United States • Boston, Massachusetts, United States +3 more locations

Active Not RecruitingNA396 miles

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

NCT02514525

To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

Barrett Esophagus

Pentax Medical150 participantsStarted Mar 2016

Orange, California, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 1472 miles

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

NCT04121676

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.

Advanced Cancer

Agenus Inc.91 participantsStarted Sep 2019

Los Angeles, California, United States • Aurora, Colorado, United States • Coral Gables, Florida, United States +9 more locations

Temporarily Not Available474 miles

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06033001

The purpose of this program is to provide access to \[Lu-177\]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials. In this program participants will be administered \[Lu-177\]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as: * Hematology blood tests * Clinical Chemistry blood tests * Testosterone/Prostate Antigen levels blood test * Vital signs * Imaging * ECG

Castration-Resistant Prostatic Cancer

Lantheus Medical Imaging

Newport Beach, California, United States • Hartford, Connecticut, United States • Jupiter, Florida, United States +4 more locations

RECRUITINGPhase 1500 miles

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more

Epigenetix, Inc.75 participantsStarted Dec 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 1665 miles

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

NCT03509012

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Carcinoma, Squamous Cell of Head and NeckCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma

AstraZeneca105 participantsStarted May 2018

Tucson, Arizona, United States • Aurora, Colorado, United States • Houston, Texas, United States +13 more locations

PreviousPage 314 of 1015Next

Diabetes

in Nashville

Heart Diseasein Nashville